Related Experiment Video
Updated: Apr 26, 2026
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
Trials in the prevention of type 1 diabetes: current and future
1Division of Endocrinology, Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.
Abstract:
A major thrust in type 1 diabetes research is stopping the destruction of beta cells that leads to type 1 diabetes. Research over the past 30 years has defined genetic factors and evidence of autoimmunity that have led to the development of robust prediction models in those at high risk for type 1 diabetes. The ability to identify those at risk and the development of new agents and of collaborative research networks has led to multiple trials aimed at preventing beta cell loss. Trials at all stages of beta cell loss have been conducted: primary prevention (prior to the development of autoimmunity); secondary prevention (after autoantibodies are found) and tertiary prevention (intervening after diagnosis to maintain remaining beta cells). Studies have shown mixed results; evidence of maintained insulin secretion after the time of diagnosis has been described in a number of studies, and primary and secondary prevention is proving to be elusive. Much has been learned from the increasing number of studies in the field in terms of network creation, study design and choice of intervention that will facilitate new avenues of investigation.
Insights
Preventing type 1 diabetes (T1D) involves stopping beta cell destruction. While prediction is improving, primary and secondary prevention of T1D remains challenging, with mixed results from intervention trials.
Area of Science:
- Immunology
- Endocrinology
- Metabolic Diseases
Background:
- Type 1 diabetes (T1D) research focuses on halting autoimmune destruction of insulin-producing beta cells.
- Genetic factors and autoimmunity evidence enable prediction models for high-risk individuals.
- Collaborative networks and new agents support trials for preventing beta cell loss.
Purpose of the Study:
- To review the progress and challenges in preventing beta cell loss in type 1 diabetes.
- To evaluate the effectiveness of primary, secondary, and tertiary prevention strategies.
- To identify lessons learned for future type 1 diabetes research.
Main Methods:
- Analysis of research over the past 30 years in type 1 diabetes.
- Review of prediction models and identification of high-risk individuals.
- Examination of clinical trials targeting different stages of beta cell loss.
Main Results:
- Mixed results reported across prevention trials for type 1 diabetes.
- Evidence of maintained insulin secretion post-diagnosis noted in some studies.
- Primary and secondary prevention strategies for type 1 diabetes have proven elusive.
Conclusions:
- Significant advancements in understanding T1D pathogenesis and risk prediction.
- Intervention trials offer valuable insights into network creation and study design.
- Future research directions are informed by current findings to advance T1D prevention efforts.
Related Concept Videos
01:12Type I Diabetes I: Introduction
01:22Diabetes Mellitus: Type 2 and Gestational
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type I Diabetes II: Pathophysiology
01:26Type II Diabetes I: Introduction
01:24Type II Diabetes II: Pathophysiology